IL-17A and TNF-α exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro

J Immunol. 2011 Mar 1;186(5):3197-205. doi: 10.4049/jimmunol.1002016. Epub 2011 Jan 31.

Abstract

CXCL5, a member of the CXC family of chemokines, contributes to neutrophil recruitment during lung inflammation, but its regulation is poorly understood. Because the T cell-derived cytokine IL-17A enhances host defense by triggering production of chemokines, particularly in combination with TNF-α, we hypothesized that IL-17A would enhance TNF-α-induced expression of CXCL5. Intratracheal coadministration of IL-17A and TNF-α in mice induced production of CXCL1, CXCL2, and CXCL5, which was associated with increased neutrophil influx in the lung at 8 and 24 h. The synergistic effects of TNF-α and IL17A were greatly attenuated in Cxcl5(-/-) mice at 24 h, but not 8 h, after exposure, a time when CXCL5 expression was at its peak in wild-type mice. Bone marrow chimeras produced using Cxcl5(-/-) donors and recipients demonstrated that lung-resident cells were the source of CXCL5. Using differentiated alveolar epithelial type II (ATII) cells derived from human fetal lung, we found that IL-17A enhanced TNF-α-induced CXCL5 transcription and stabilized TNF-α-induced CXCL5 transcripts. Whereas expression of CXCL5 required activation of NF-κB, IL-17A did not increase TNF-α-induced NF-κB activation. Apical costimulation of IL-17A and TNF-α provoked apical secretion of CXCL5 by human ATII cells in a transwell system, whereas basolateral costimulation led to both apical and basolateral secretion of CXCL5. The observation that human ATII cells secrete CXCL5 in a polarized fashion may represent a mechanism to recruit neutrophils in host defense in a fashion that discriminates the site of initial injury.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Lung Injury / genetics
  • Acute Lung Injury / immunology
  • Acute Lung Injury / pathology
  • Animals
  • Cell Migration Inhibition / genetics
  • Cell Migration Inhibition / immunology
  • Cells, Cultured
  • Chemokine CXCL1 / biosynthesis
  • Chemokine CXCL2 / biosynthesis
  • Chemokine CXCL5 / biosynthesis*
  • Chemokine CXCL5 / deficiency
  • Chemokine CXCL5 / metabolism
  • Chemotaxis, Leukocyte / genetics
  • Chemotaxis, Leukocyte / immunology
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Humans
  • Inflammation Mediators / metabolism
  • Inflammation Mediators / physiology
  • Interleukin-17 / administration & dosage
  • Interleukin-17 / biosynthesis
  • Interleukin-17 / physiology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neutrophils / immunology
  • Neutrophils / pathology
  • Pneumonia, Bacterial / immunology
  • Pneumonia, Bacterial / metabolism
  • Pneumonia, Bacterial / pathology
  • Pulmonary Alveoli / immunology*
  • Pulmonary Alveoli / metabolism*
  • Pulmonary Alveoli / pathology
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / biosynthesis
  • Severity of Illness Index
  • Signal Transduction / genetics
  • Signal Transduction / immunology
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / physiology*

Substances

  • CXCL5 protein, human
  • Chemokine CXCL1
  • Chemokine CXCL2
  • Chemokine CXCL5
  • Cxcl1 protein, mouse
  • Cxcl2 protein, mouse
  • Cxcl5 protein, mouse
  • IL17A protein, human
  • Inflammation Mediators
  • Interleukin-17
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha